Literature DB >> 9725240

CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge.

A M Krieg1, L Love-Homan, A K Yi, J T Harty.   

Abstract

Vertebrates have evolved innate immune defense mechanisms that recognize and respond to structural patterns that are specific to microbial molecules. One such pattern recognition system is based on unmethylated CpG dinucleotides in particular sequence contexts (CpG motifs); these motifs are common in bacterial DNA but are under-represented ("CpG suppression") and methylated in vertebrate DNA. Mice that are injected with bacterial DNA or synthetic oligodeoxynucleotides (ODNs) containing CpG motifs respond with a rapid production of IL-12 and IFN-gamma. The serum levels of IL-12 were increased for at least 8 days after a single injection of CpG ODNs, but IFN-gamma levels returned to baseline within 24 h. This Th1-like cytokine response to CpG motifs induces a state of resistance to infection by Listeria monocytogenes in susceptible specific pathogen-free BALB/c mice. Resistance developed within 48 h of pretreatment with CpG ODNs, persisted for at least 2 wk, and was dependent upon IFN-gamma secretion. These data support the hypothesis that CpG DNA motifs are a "danger signal" that activates protective innate immune defenses and may have therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9725240

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  78 in total

1.  Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection.

Authors:  D M Klinman; J Conover; C Coban
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

Review 2.  Signal transduction induced by immunostimulatory CpG DNA.

Authors:  A M Krieg
Journal:  Springer Semin Immunopathol       Date:  2000

Review 3.  Immunostimulatory DNA sequences help to eradicate intracellular pathogens.

Authors:  H Wagner; H Häcker; G B Lipford
Journal:  Springer Semin Immunopathol       Date:  2000

4.  Plasmid DNA modulates chronic graft-versus-host reaction.

Authors:  V V Vlasov; E Yu Rykova; I V Safronova; P P Lactionov; O T Kudaeva; V A Kozlov
Journal:  Dokl Biol Sci       Date:  2002 Jan-Feb

5.  Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes.

Authors:  Malgorzata Gierynska; Uday Kumaraguru; Seong-Kug Eo; Sujin Lee; Arthur Krieg; Barry T Rouse
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

6.  The use of CpG as an adjuvant to Toxoplasma gondii vaccination.

Authors:  Jennifer A Spencer; Bruce F Smith; Anthony J Guarino; Byron L Blagburn; Henry J Baker
Journal:  Parasitol Res       Date:  2004-01-15       Impact factor: 2.289

7.  Activation of type I interferon-dependent genes characterizes the "core response" induced by CpG DNA.

Authors:  Folkert Steinhagen; Corinna Meyer; Debra Tross; Mayda Gursel; Takahiro Maeda; Sven Klaschik; Dennis M Klinman
Journal:  J Leukoc Biol       Date:  2012-07-02       Impact factor: 4.962

8.  Innate immune responses induced by CpG oligodeoxyribonucleotide stimulation of ovine blood mononuclear cells.

Authors:  Angelo Mena; Anil K Nichani; Yurij Popowych; Dale L Godson; Donna Dent; Hugh G G Townsend; George K Mutwiri; Rolf Hecker; Lorne A Babiuk; Philip Griebel
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

9.  Short- and long-term changes in gene expression mediated by the activation of TLR9.

Authors:  Sven Klaschik; Debra Tross; Hidekazu Shirota; Dennis M Klinman
Journal:  Mol Immunol       Date:  2009-12-14       Impact factor: 4.407

10.  Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.

Authors:  A Al-Mariri; A Tibor; P Mertens; X De Bolle; P Michel; J Godefroid; K Walravens; J J Letesson
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.